Table 1

Demographic and clinical characteristics at baseline

All patients (n=292)Good responders (n=103)Moderate responders (n=115)Non-responders (n=74)
Demographics
 Age, years52.8±12.750.5±11.754.4±12.753.7±13.8
 Female, n (%)239 (82)79 (77)95 (83)65 (88)
 Body mass index26.0±5.625.9±5.425.7±5.226.7±6.5
 Smoking, n (%)77 (27)32 (32)29 (26)16 (22)
 Glomerular filtration rate§118.6±39.3121.5±38.1114.6±39.8120.6±40.7
DMARD and previous biological therapy
 Previous DMARD2.9±1.22.7±1.1*3.0±1.43.0±1.3*
 Methotrexate use, n (%)223 (76)82 (80)87 (76)54 (73)
 Methotrexate dose, mg/week19.7±7.020.9±6.319.3±7.518.8±7.2
 Prednisone use, n (%)83 (28)26 (25)35 (30)22 (30)
 Prednisone dose, mg/day8.2±3.97.3±4.18.5±3.98.6±3.7
 Other DMARD than methotrexate, n (%)96 (33)41 (40)34 (30)21 (28)
 Previous biological agent, n (%)89 (31)19 (18)*41 (36)29 (39)*
Disease status
 Disease duration, years8 (3–16)8 (2–4)9 (3–8)7 (3–7)
 Rheumatoid factor, n (%)207 (72)74 (73)84 (74)49 (66)
 Erosive disease, n (%)206 (72)70 (69)83 (74)53 (72)
 HAQ1.3±0.71.2±0.81.4±0.71.3±0.7
 DAS285.2±1.35.0±1.25.7±1.2**4.7±1.5**
 Erythrocyte sedimentation rate, mm/h23 (12–0)17 (9–31)29 (14–46)**20 (10–40)**
 C-reactive protein, mg/l8 (3–1)6 (3–20)11 (4–23)**6 (2–17)**
  • Mean values±SD, median and IQR, or percentages are shown.

  • * There was a significant difference between EULAR good and non-responders for previous DMARD (p=0.047) and previous biological agent use (p=0.002).

  • Last observation carried forward data were used for patients who discontinued the treatment with etanercept before 6 months.

  • There was a significant difference between good and moderate EULAR responders for age (p=0.017); previous DMARD (p=0.0034); DAS28 (p<0.001); previous biological agent use (p=0.005); disease duration (p=0.038) and erythrocyte sedimentation rate (p<0.001).

  • § Glomerular filtration rate according to the Cockcroft–Gault formula.

  • Previous biological agents consisted of infliximab and adalimumab.

  • ** There was a significant difference between moderate and EULAR non-responders for DAS28 (p<0.001); erythrocyte sedimentation rate (p=0.039); C-reactive protein (p=0.033).

  • DAS28, disease activity score in 28 joints; DMARD, disease-modifying antirheumatic drug; EULAR, European League Against Rheumatism; HAQ, health assessment questionnaire.